<SEC-DOCUMENT>0001062993-16-006980.txt : 20160111
<SEC-HEADER>0001062993-16-006980.hdr.sgml : 20160111
<ACCEPTANCE-DATETIME>20160111085553
ACCESSION NUMBER:		0001062993-16-006980
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160107
ITEM INFORMATION:		Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160111
DATE AS OF CHANGE:		20160111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HELIUS MEDICAL TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001610853
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			WY
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55364
		FILM NUMBER:		161335222

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 400, 41 UNIVERSITY DRIVE
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
		BUSINESS PHONE:		215-809-2018

	MAIL ADDRESS:	
		STREET 1:		SUITE 400, 41 UNIVERSITY DRIVE
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Helius Medical Technologies, Inc.: Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT><BR></B><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR></B>Washington, DC 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT <BR></B><B>Pursuant to Section 13 or 15(d) of
the <BR></B><B>Securities Exchange Act of 1934 </B></P>
<P align=center>Date of report (Date of earliest event reported): <B><U>January
11, 2016 (January 7, 2016)</U></B><B> </B></P>
<P align=center><B><U><FONT size=5>HELIUS MEDICAL TECHNOLOGIES,
INC.</FONT></U></B><B> <BR></B>(Exact Name of Registrant as Specified in
Charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Wyoming </U></B></TD>
    <TD align=center width="33%"><B><U>000-55364 </U></B></TD>
    <TD align=center width="33%"><B><U>36-4787690 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or Other Jurisdiction </TD>
    <TD align=center width="33%">(Commission </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>of Incorporation) </TD>
    <TD align=center width="33%">File Number) </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B>Suite 400, 41 University Drive </B></TD>
    <TD align=left width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center><B><U>Newtown, Pennsylvania </U></B></TD>
    <TD align=center width="50%"><B><U>18940 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(Address of Principal Executive Offices) </TD>
    <TD align=center width="50%">(Zip Code) </TD></TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(215)
809-2018 </U></B></P>
<P align=center>____________________________________________________<BR>(Former
Name or Former Address, if Changed Since Last Report) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (<I>see </I>General Instruction A.2. below):
</P>
<P align=justify>[&nbsp; ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) </P>
<P align=justify>[ &nbsp;] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12) </P>
<P align=justify>[&nbsp; ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) </P>
<P align=justify>[&nbsp; ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) </P>

<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A><P align=justify><B><U>Item 4.02 Non-Reliance on Previously Issued Financial
Statements or a Related Audit Report or Completed</U></B><B> </B><B><U>Interim
Review. </U></B></P>
<P align=justify>(a) On January <b>7</b>, 2016, the Audit Committee of the
Board of Directors (the &#147;Audit Committee&#148;) of Helius Medical Technologies, Inc.
(the &#147;Company&#148;), after considering the recommendations of management, concluded
that the Company&#146;s consolidated financial statements as of and for the twelve
months ended March 31, 2015 and the quarters therein and its interim condensed
consolidated financial statements for the three months ended June 30, 2015 and
the three months and six months ended September 30, 2015
(collectively, the &#147;Non-Reliance Periods&#148;), as reported in the Company&#146;s Annual
Report on Form 10-K filed on June 29, 2015 and Quarterly Reports on Forms 10-Q
filed on August 14, 2015 and November 16, 2015, should not be relied upon
because of errors identified therein. Accordingly, investors, analysts and other
persons should not rely upon the Company&#146;s previously released financial
statements and other financial data for the Non-Reliance Periods or any press
releases, investor presentations or other communications that relate to that
information. </P>
<P align=justify>The Audit Committee determined the fair value of the Company&#146;s
  unvested share based compensation for non-employee consultants should have been
  re-measured at the respective fair values until the services have been completed
  or once the options have vested. Under the terms of the Company&#146;s stock option
  awards to non-employees, there were no performance disincentives. As a result
  the Company is required to re-measure its non-employee awards until they have
vested. </P>
<P align=justify>The Audit Committee and the Company&#146;s executive management have
discussed the matters disclosed in this filing pursuant to Item 4.02(a) with the
Company&#146;s independent registered accounting firm, BDO Canada LLP (the
&#147;Auditor&#148;). The Auditor agrees with the conclusion that the financial statements
for the Non-Reliance Periods should no longer be relied upon.</P>
<P align=justify>The Company anticipates that it will file restated
financial statements covering the Non-Reliance Periods on or about January 11,
2016. Management is also evaluating the Company&#146;s disclosure controls and
procedures and internal controls over financial reporting and will provide final
evaluations in the amended filings. </P>
<P align=justify>While the Company is continuing to perform a detailed review of
its previously reported financial information, the Company currently anticipates
that the effect on each of its financial statements for the Non-Reliance Periods
will be material but will be a non-cash item on the Company&#146;s financial
statements and will not affect the Company&#146;s cash position, the extent of any
potential dilution to the Company&#146;s stockholders or any future cash flows of the
Company. </P>
<P align=justify>On January 11, 2016, the Company issued a press release
announcing the information discussed in this Item 4.02. A copy of the press
release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
</P>
<P align=justify><B><U>Item 9.01 Financial Statements and Exhibits. </U></B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify>Exhibits:</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD noWrap align=left><B>Exhibit </B></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD noWrap align=left width="88%"><B>Description </B></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=left><B>Number
      </B></TD>
    <TD noWrap align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" noWrap align=left
      width="88%">&nbsp; </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="88%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="2%" bgColor=#eeeeee>&nbsp;</TD>
    <TD align=left width="88%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press release, dated January
    11, 2016. </a></TD>
  </TR></TABLE>

<P align=center>2 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A><P align=center><B>SIGNATURES </B></P>
<P align=justify style="text-indent:5%">Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="5%"></TD>
    <TD align=left width="45%">HELIUS MEDICAL TECHNOLOGIES, INC. </TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: January 11, 2016 </TD>
    <TD align=left width="5%">&nbsp;</TD>
    <TD align=left width="45%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="5%">By: </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="45%">&nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<I>/s/ Joyce
      LaViscount </I></TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="5%">Name: </TD>
    <TD align=left width="45%">Joyce LaViscount </TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="5%">Title: </TD>
    <TD align=left width="45%">Chief Financial Officer </TD></TR></TABLE>
<P align=center><U>Exhibit Index </U></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=top noWrap align=left
    ><B>Exhibit Number </B></TD>
    <TD vAlign=top noWrap align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=top noWrap align=center
    width="88%"><B>Description </B></TD></TR>
  <TR>
    <TD vAlign=bottom noWrap align=left >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom noWrap align=left width="88%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee ><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="2%"  bgColor=#eeeeee
    >&nbsp;</TD>
    <TD align=left width="88%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press release, dated January
    11, 2016. </a></TD>
  </TR></TABLE>
<P align=center>3 </P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Helius Medical Technologies, Inc.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=right><IMG src="exhibit99-1x1x1.jpg" border=0 width="205" height="111"> </P>
<P align=center><B>Helius Medical Technologies Restates and Re-files
<BR>Historical Financial Statements </B></P>
<P align=justify>NEWTOWN, PA &#150; January 11, 2016 &#150; Helius Medical Technologies,
Inc. (CSE: HSM) (OTCQB: HSDT) (&#147;<B>HMT</B>&#148;, or the &#147;<B>Company</B>&#148;) &#150; The
Company is issuing the following press release to clarify its disclosure.</P>
<P align=justify><B>Restated Financial Statements </B></P>
<P align=justify>The Company has restated its audited annual financial
statements for the fiscal year ended March 31, 2015, and its interim financial
statements for the periods ended June 30, 2015 and September 30, 2015
(collectively, the &#147;Restated Financial Statements&#148;) in order to reflect the
correction of an error in the re-measurement of unvested non-employee stock option awards. The Company is filing amended versions of its Annual
Report on Form 10-K for the fiscal year ended March 31, 2015, originally filed
on June 29, 2015, and its Quarterly Reports on Form 10-Q for the interim periods
ended June 30, 2015 and September 30, 2015, originally filed on August 14, 2015
and November 16, 2015, respectively, with the Restated Financial Statements and
corresponding changes to the management&#146;s discussion and analysis for the
above-noted periods and other portion of such filings. </P>
<P align=justify>Previously, the Company had recorded the stock-based
compensation for the fiscal year ended March 31, 2015 and the interim periods
ended June 30, 2015 and September 30, 2015 based on the fair value of
the awards on their respective grant dates. Under the provisions of ASC 505-50,
the Company is required to measure stock-based compensation at the earlier of
the performance commitment date or the date that the services have been
completed. A performance commitment date exists only when the counterparty has
sufficient disincentive not to complete. Otherwise, the Company is required to
re-measure unvested non-employee options at their respective fair values until
the services have been completed or once the options have vested. Under the
terms of the Company&#146;s stock option awards to non-employees, there were no
performance disincentives. As a result, the Company is required to re-measure
its non-employee awards until they have vested. </P>
<P align=justify>As a result of the restatements, adjustments made to the
Company&#146;s financial statements for the year ended March 31, 2015 are shown in
Exhibit 1 to this news release. Adjustments made to the Company&#146;s financial
statements for the interim period ended June 30, 2015 are shown in Exhibit 2,
and adjustments made to the Company&#146;s financial statements for the interim
period ended September 30, 2015 are shown in Exhibit 3. </P>
<P align=justify><B>About Helius Medical Technologies (HMT) </B></P>
<P align=justify>Helius Medical Technologies is a medical technology company
focused on neurological wellness. HMT seeks to develop, license and acquire
unique and non-invasive platform technologies that amplify the brain&#146;s ability
to heal itself. HMT intends to file for U.S. Food and Drug Administration
clearance for the PoNS&#153; device. For more information, please visit <U>www.heliusmedical.com</U>. The contents of this website are
not, and should not be deemed to be, incorporated by reference herein. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify><B>Cautionary Disclaimer Statement: </B></P>
<P align=justify><I>The Canadian Securities Exchange has not reviewed and does
  not accept responsibility for the adequacy or accuracy of the content of this
news release</I>. </P>
<P align=justify>Forward-looking statements are often identified by terms such
as &#147;will&#148;, &#147;may&#148;, &#147;should&#148;, &#147;anticipate&#148;, &#147;expects&#148; and similar expressions. All
statements other than statements of historical fact, included in this release
are forward-looking statements that involve risks and uncertainties. There can
be no assurance that such statements will prove to be accurate and actual
results and future events could differ materially from those anticipated in such
statements. Important factors that could cause actual results to differ
materially from the Company&#146;s expectations include the failure to satisfy the
conditions of the Canadian Securities Exchange and other risks detailed from
time to time in the filings made by the Company with securities regulations.
</P>
<P align=justify>The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be incorrect. Events
or circumstances may cause actual results to differ materially from those
predicted, as a result of numerous known and unknown risks, uncertainties, and
other factors, many of which are beyond the control of the Company. The reader
is cautioned not to place undue reliance on any forward-looking information.
Such information, although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may differ materially
from those anticipated. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made as of the
date of this news release and the Company will update or revise publicly any of
the included forward-looking statements as expressly required by applicable law.
</P>
<P align=center># # # </P>
<P align=justify>Contact: </P>
<P align=justify>Corporate Contact: </P>
<P style="MARGIN-LEFT: 10%" align=justify>Phil Deschamps <BR>614-596-2597
<BR><U>pdeschamps@heliusmedical.com</U> </P>
<P align=justify>Investor Relations: </P>
<P style="MARGIN-LEFT: 10%" align=justify>778-588-7144
<BR><U>info@heliusmedical.com</U> </P>
<P align=justify>Media Contact: </P>
<P style="MARGIN-LEFT: 10%" align=justify>Becky Kern<BR>914-772-2310
<BR>media@heliusmedical.com <BR></P>
<P align=justify><B>Exhibit 1</B> &#150; Adjustments to March 31, 2015 financial
statements </P>
<DIV>
   <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=center noWrap>&nbsp; </TD>
    <TD width="23%" align=center noWrap><B>As Originally Reported</B> </TD>
    <TD width="23%" align=center noWrap><B>Adjustment</B> </TD>
    <TD width="23%" align=center noWrap><B>As Restated</B> </TD>
  </TR>
  <TR>
    <TD noWrap align=center >&nbsp;</TD>
    <TD noWrap align=center >&nbsp;</TD>
    <TD noWrap align=center >&nbsp;</TD>
    <TD noWrap align=center >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees </TD>
    <TD align=right>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$1,085,606 </TD>
    <TD align=right>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    &nbsp;$272,464</TD>
    <TD align=right>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp;$1,358,070 </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right >&nbsp;</TD>
    <TD align=right >&nbsp;</TD>
    <TD align=right
>&nbsp;</TD>
  <TR vAlign=top>
    <TD align=left>Research &amp; development expenses </TD>
    <TD align=right>$3,828,775 </TD>
    <TD align=right>$671,298 </TD>
    <TD align=right>$4,500,073 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left>&nbsp; </TD>
    <TD align=left>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Net loss for the year </TD>
    <TD align=right>$8,894,555 </TD>
    <TD align=right>$943,762 </TD>
    <TD align=right>$9,838,317 </TD>
  </TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Comprehensive loss for the year </TD>
    <TD align=right>$9,866,195 </TD>
    <TD align=right>$943,762 </TD>
    <TD align=right>$10,809,957 </TD>
  </TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Basic and diluted loss per share </TD>
    <TD align=right>$(0.16) </TD>
    <TD align=right>$(0.01) </TD>
    <TD align=right>$(0.17) </TD>
  </TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Additional paid-in capital </TD>
    <TD align=right>1,490,790 </TD>
    <TD align=right>$943,762 </TD>
    <TD align=right>$2,434,552 </TD>
  </TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Accumulated deficit </TD>
    <TD align=right>$(18,479,689) </TD>
    <TD align=right>$(943,762) </TD>
    <TD align=right>(19,423,451) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
    <TD align=right>&nbsp;</TD>
  </TR>
  </TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A>
<P align=justify><B>Exhibit 2</B> &#150; Adjustments to June 30, 2015 financial
statements </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=left>&nbsp; </TD>
    <TD vAlign=bottom noWrap align=center colSpan=3><B>June 30,
      2015</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=left></TD>
    <TD width="23%" align=right vAlign=bottom noWrap><B>As originally</B>
      <BR>
    <B>reported</B> </TD>
    <TD width="23%" align=right vAlign=bottom noWrap><B>Adjustment</B> </TD>
  <TD width="23%" align=right vAlign=bottom noWrap><B>As restated</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees </TD>
    <TD align=right>$142,822 </TD>
    <TD align=right>($36,835) </TD>
  <TD align=right>$105,987 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Research and development </TD>
    <TD align=right>$1,386,676 </TD>
    <TD align=right>$(15,750) </TD>
  <TD align=right>$1,370,926 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Wages and salaries </TD>
    <TD align=right>$439,065 </TD>
    <TD align=right>$53,362 </TD>
  <TD align=right>$492,427 </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
  <TD>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Change in fair value of derivative liability </TD>
    <TD align=right>$(178,378) </TD>
    <TD align=right>$583,850 </TD>
  <TD align=right>$405,472 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Net loss for the year </TD>
    <TD align=right>$(3,094,854) </TD>
    <TD align=right>$583,073 </TD>
  <TD align=right>$(2,511,781) </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
  <TD>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Comprehensive loss for the year </TD>
    <TD align=right>$(3,054,228) </TD>
    <TD align=right>$583,073 </TD>
  <TD align=right>$(2,471,155) </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
  <TD>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Basic and diluted loss per share </TD>
    <TD align=right>$(0.05) </TD>
    <TD align=right>$0.01 </TD>
  <TD align=right>$(0.04) </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
  <TD>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Additional paid-in capital </TD>
    <TD align=right>$1,713,992 </TD>
    <TD align=right>$360,689 </TD>
  <TD align=right>$2,074,681 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Accumulated deficit </TD>
    <TD align=right>$(21,574,543) </TD>
    <TD align=right>$(360,689) </TD>
  <TD align=right>$(21,935,232) </TD>
  </TR></TABLE><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left vAlign=bottom noWrap>&nbsp; </TD>
    <TD vAlign=bottom noWrap align=center colSpan=3><B>June 30,
      2014</B> </TD></TR>
  <TR vAlign=top>
    <TD vAlign=bottom noWrap align=right><BR></TD>
    <TD width="23%" align=right vAlign=bottom noWrap><B>As originally</B>
      <BR>
      <B>reported</B> </TD>
    <TD width="23%" align=right vAlign=bottom noWrap><B>Adjustment</B> </TD>
    <TD width="23%" align=right vAlign=bottom noWrap><B>As restated</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees </TD>
    <TD align=right>$200,849 </TD>
    <TD align=right>$(149,526) </TD>
    <TD align=right>$51,323 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Research and development </TD>
    <TD align=right>$653,259 </TD>
    <TD align=right>$97,095 </TD>
    <TD align=right>$750,354 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Wages and salaries </TD>
    <TD align=right>$170,981</TD>
    <TD align=right>$47,630 </TD>
    <TD align=right>$218,611 </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Net loss for the year </TD>
    <TD align=right>$(1,568,754) </TD>
    <TD align=right>$4,801 </TD>
    <TD align=right>$(1,563,953) </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Comprehensive loss for the year </TD>
    <TD align=right>$(1,462,695) </TD>
    <TD align=right>$4,801 </TD>
    <TD align=right>$(1,457,894) </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Basic and diluted loss per share </TD>
    <TD align=right>$(0.04) </TD>
    <TD align=right>$- </TD>
    <TD align=right>$(0.04) </TD>
  </TR></TABLE>
</DIV>
<P align=justify><B>Exhibit 3</B> &#150; Adjustments to September 30, 2015 financial
statements </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=center vAlign=top noWrap></TD>
    <TD vAlign=top noWrap align=center colSpan=3><B>Three months
      ended September 30, 2015</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD vAlign=top noWrap align=center><BR></TD>
    <TD width="23%" align=center vAlign=top noWrap><B>As
      Originally</B> <BR>
      <STRONG>Reported</STRONG> </TD>
    <TD width="23%" align=center vAlign=top noWrap><B>Adjustment</B>
      <BR></TD>
    <TD width="23%" align=center vAlign=top noWrap><B>As
    Restated</B> <BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees </TD>
    <TD align=left>
    <p align="right">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;$20,199 </TD>
    <TD align=right>$(45,191) </TD>
    <TD align=right>$(24,992) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Research and development </TD>
    <TD align=left>
    <p align="right">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;243,262 </TD>
    <TD align=right>$(241,731) </TD>
    <TD align=right>$1,531 </TD>
  <TR vAlign=top>
    <TD align=left>Wages and salaries </TD>
    <TD align=right>$223,349 </TD>
    <TD align=right>$(48,998) </TD>
    <TD align=right>$174,351 </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Net income (loss) for the period </TD>
    <TD align=right>$1,039,361 </TD>
    <TD align=right>$335,920 </TD>
    <TD align=right>$1,375,281 </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Comprehensive income (loss) for the period </TD>
    <TD align=right>$475,078 </TD>
    <TD align=right>$332,684 </TD>
    <TD align=right>$807,762 </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
    <TD>&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Basic and diluted loss per share </TD>
    <TD align=right>$(0.02) </TD>
    <TD align=right>$- </TD>
    <TD align=right>$(0.02) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left colSpan=4>&nbsp;</TD></TR></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD vAlign=top noWrap align=center></TD>
    <TD vAlign=top noWrap align=center width="69%" colSpan=3><B>Six months
      ended September 30, 2015</B> </TD></TR>
  <TR vAlign=top>
    <TD vAlign=top noWrap align=center><BR></TD>
    <TD vAlign=top noWrap align=center width="23%"><B>As Originally</B>
      <BR><B>Reported</B> </TD>
    <TD vAlign=top noWrap align=center width="23%"><B>Adjustment</B> </TD>
    <TD vAlign=top noWrap align=center width="23%"><B>As Restated</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees </TD>
    <TD align=right width="23%">$163,021 </TD>
    <TD align=right width="23%">$(82,026) </TD>
    <TD align=right width="23%">$80,995 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Research and development </TD>
    <TD align=right width="23%">1,629,938 </TD>
    <TD align=right width="23%">$(257,481) </TD>
    <TD align=right width="23%">$1,372,457 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Wages and salaries </TD>
    <TD align=right width="23%">$662,414 </TD>
    <TD align=right width="23%">$4,364 </TD>
    <TD align=right width="23%">$666,778 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Change in fair value of derivative liability </TD>
    <TD align=right width="23%">$(1,305,796) </TD>
    <TD align=right width="23%">$(583,850) </TD>
    <TD align=right width="23%">$(1,889,646) </TD>
  </TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Net income (loss) for the period </TD>
    <TD align=right width="23%">$(2,055,493) </TD>
    <TD align=right width="23%">$918,993 </TD>
    <TD align=right width="23%">$(1,136,500) </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Comprehensive income (loss) for the period </TD>
    <TD align=right width="23%">$(2,582,386) </TD>
    <TD align=right width="23%">$918,993 </TD>
    <TD align=right width="23%">$(1,663,393) </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Basic and diluted loss per share </TD>
    <TD align=right width="23%">$(0.03) </TD>
    <TD align=right width="23%">$0.01 </TD>
    <TD align=right width="23%">$(0.02) </TD></TR></TABLE><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD vAlign=top noWrap align=center></TD>
    <TD vAlign=top noWrap align=center width="69%" colSpan=3><B>As at
      September 30, 2015</B> </TD></TR>
  <TR vAlign=top>
    <TD vAlign=top noWrap align=center><BR></TD>
    <TD vAlign=top noWrap align=center width="23%"><B>As Originally</B>
      <BR><B>Reported</B> </TD>
    <TD vAlign=top noWrap align=center width="23%"><B>Adjustment</B> </TD>
    <TD vAlign=top noWrap align=center width="23%"><B>As Restated</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Additional paid-in capital </TD>
    <TD align=right width="23%">$1,819,735 </TD>
    <TD align=right width="23%">$24,769 </TD>
    <TD align=right width="23%">$1,844,504 </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Accumulated deficit </TD>
    <TD align=right width="23%">$(20,535,182) </TD>
    <TD align=right width="23%">$(24,769) </TD>
    <TD align=right width="23%">$(20,559,951) </TD></TR></TABLE></DIV><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD noWrap align=left></TD>
    <TD noWrap align=center width="69%" colSpan=3>&nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<B>Three months ended September
      30, 2014</B> </TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left><BR></TD>
    <TD noWrap align=center width="23%"><B>As Originally</B>
      <BR><STRONG>Reported</STRONG> </TD>
    <TD noWrap align=center width="23%"><B>Adjustment</B> </TD>
    <TD noWrap align=right width="23%"><B>As Restated</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees </TD>
    <TD align=right width="23%">$36,013 </TD>
    <TD align=right width="23%">$179,017 </TD>
    <TD align=right width="23%">$215,030 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Research and development </TD>
    <TD align=right width="23%">$1,062,927 </TD>
    <TD align=right width="23%">$191,259 </TD>
    <TD align=right width="23%">$1,254,186 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Wages and salaries </TD>
    <TD align=right width="23%">$295,017 </TD>
    <TD align=right width="23%">$38,628 </TD>
    <TD align=right width="23%">$333,645 </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Net income (loss) for the period </TD>
    <TD align=right width="23%">$(3,347,223) </TD>
    <TD align=right width="23%">$(408,904) </TD>
    <TD align=right width="23%">$(3,756,127) </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Comprehensive income (loss) for the period </TD>
    <TD align=right width="23%">$(3,140,437) </TD>
    <TD align=right width="23%">$(408,904) </TD>
    <TD align=right width="23%">$(3,549,341) </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD>
    <TD width="23%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Basic and diluted loss per share </TD>
    <TD align=right width="23%">$(0.05) </TD>
    <TD align=right width="23%">$(0.01) </TD>
    <TD align=right width="23%">$(0.06) </TD></TR>
  <TR vAlign=top>
    <TD align=left colSpan=4>&nbsp;</TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD vAlign=top noWrap align=center></TD>
    <TD vAlign=top noWrap align=center width="69%" colSpan=3><B>Six months
      ended September 30, 2014</B> </TD></TR>
  <TR vAlign=top>
    <TD vAlign=top noWrap align=center></TD>
    <TD vAlign=top noWrap align=center width="23%"><B>As Originally</B>
      <BR><B>Reported</B> </TD>
    <TD vAlign=top noWrap align=center width="23%"><B>Adjustment</B> </TD>
    <TD vAlign=top noWrap align=center width="23%"><B>As Restated</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees </TD>
    <TD align=right width="23%">$236,862 </TD>
    <TD align=right width="23%">$29,491 </TD>
    <TD align=right width="23%">$266,353 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Research and development </TD>
    <TD align=right width="23%">$1,716,186 </TD>
    <TD align=right width="23%">$288,354 </TD>
    <TD align=right width="23%">$2,004,540 </TD>  <TR vAlign=top>
    <TD align=left>Wages and salaries </TD>
    <TD align=right width="23%">$465,998 </TD>
    <TD align=right width="23%">$86,258 </TD>
    <TD align=right width="23%">$552,256 </TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=right width="23%">&nbsp;</TD>
    <TD align=right width="23%">&nbsp;</TD>
    <TD align=right width="23%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Net loss for the period </TD>
    <TD align=right width="23%">$(4,915,977) </TD>
    <TD align=right width="23%">$(404,103) </TD>
    <TD align=right width="23%">$(5,320,080) </TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=right width="23%">&nbsp;</TD>
    <TD align=right width="23%">&nbsp;</TD>
    <TD align=right width="23%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Comprehensive loss for the period </TD>
    <TD align=right width="23%">$(4,603,132) </TD>
    <TD align=right width="23%">$(404,103) </TD>
    <TD align=right width="23%">$(5,007,235) </TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=right width="23%">&nbsp;</TD>
    <TD align=right width="23%">&nbsp;</TD>
    <TD align=right width="23%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Basic and diluted loss per share </TD>
    <TD align=right width="23%">$(0.10) </TD>
    <TD align=right width="23%">$- </TD>
    <TD align=right width="23%">$(0.10) </TD></TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="23%">&nbsp; </TD>
    <TD align=left width="23%">&nbsp; </TD>
    <TD align=left width="23%">&nbsp; </TD></TR></TR></TABLE></DIV><BR>

<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit99-1x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99-1x1x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" !O ,T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T"BDHH 6B
MHEN(FF,*N"X&2!VJ2DFF%K"T444P"BBB@ HHHH **** "BBB@ HHHH ****
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MBNO^/67_ '&_E6/_ ,)3:_\ /";]/\:9-XFMI(7002@LI':D!D^'O^0U;_\
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M?^@FK7BFU:.^%P!\DJ@9]Q_D4P'0:[?Q01QI9H510H.QN@%17NK7U[:O!):
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MJ2B@#&>"8:,J;) XFW85<L!YF<@?2E=9F>VN=MQ,L#MN5T"L<C&0!C.*V**
M,RX$MY-:/&LT 5WRQ49 V]<'/7WJL;"2:-89ED8&Z=F<C!QM.&_.MRB@#GX[
M:\#SR31%W2>-SM'^L"C&1_.IKU);OSYH[>55$'E@,N&<[@>GMBMJB@#,N)7G
M>"9+><B"3<R,F"001D>N*@N(9KN2:X2!PH\O".,&3:V3Q6U10!BW+75S'<JJ
M3F(Q_*KQA2&R.!W/%2,)8]5G?_251F0CRXP5; &<G%:U% &6HEBU#%NDZH\A
0,JNOR8_O ]OI6I110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
